<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02792504</url>
  </required_header>
  <id_info>
    <org_study_id>B2311067</org_study_id>
    <nct_id>NCT02792504</nct_id>
  </id_info>
  <brief_title>Post Marketing Surveillance To Observe Safety And Efficacy Of Duavive</brief_title>
  <official_title>Post Marketing Surveillance To Observe Safety And Efficacy Of Duavive Tab 0.45mg/20mg</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate safety and efficacy of CE/BZA in real practice in Korea
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 23, 2016</start_date>
  <completion_date type="Anticipated">January 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>30 days after last dose</time_frame>
    <description>Counts of participants who had treatment-emergent adverse events (TEAEs), defined as newly occurring or worsening after first dose. Relatedness to [study drug] was assessed by the investigator (Yes/No). Participants with multiple occurrences of an AE within a category were counted once within the category.
Percentage of participants discontinued from study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vasomotor System Assessment</measure>
    <time_frame>30 days after last dose</time_frame>
    <description>Measured as follows (improved, no change, aggravated), investigators judgment on the improvement of the symptom recorded during the treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Osteopenia Assessment</measure>
    <time_frame>30 days after last dose</time_frame>
    <description>Measured as follows (improved, no change, aggravated), investigators judgment on clincal response at post treatment and relevant lab data(if collected)from medical record during the treatment.</description>
  </primary_outcome>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Severe Vasomotor Symptom Associated With Menopause</condition>
  <eligibility>
    <study_pop>
      <textblock>
        General hospital and Primary clinic in Korea
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Severe post menopausal vasomotor symptoms with uterus

          2. postmenopausal osteopenia

        Exclusion Criteria:

          -  Women with undiagnosed abnormal uterine bleeding

          -  Women with known, suspected, or past history of breast cancer

          -  Women with known or suspected estrogen-dependent neoplasia

          -  Women with active deep venous thrombosis, pulmonary embolism, or history of these
             conditions

          -  Women with active arterial thromboembolic disease (for example, stroke, myocardial
             infarction) or history of these conditions

          -  Women who are receiving progestin, estrogen, or estrogen-agonists/antagonists

          -  Women with hypersensitivity (for example, anaphylaxis, angioedema) to estrogens,
             bazedoxifene, or any ingredients

          -  Women with known hepatic impairment or disease

          -  Women with known protein C, protein S, or antithrombin deficiency or other known
             thrombophilic disorders

          -  Pregnant women, women who may become pregnant, and nursing mothers

          -  Women with hereditary problems of galactose intolerance, Lapp lactase deficiency or
             glucose galactose malabsorption.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kyungpook National University/Department of Internal Medicine (Cardiology)</name>
      <address>
        <city>Jung-gu</city>
        <state>Daegu</state>
        <zip>700-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr. Wang's OB &amp; GY Clinic</name>
      <address>
        <city>Seoul</city>
        <state>Dobong-gu</state>
        <zip>01432</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kimhyeonmi OBGY</name>
      <address>
        <city>Hwaseong-si</city>
        <state>Dongtan</state>
        <zip>18442</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Korea University Ansan Hospital</name>
      <address>
        <city>Ansan</city>
        <state>Gyeonggi-do</state>
        <zip>425-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Baylor Ewha Obgyn Clinic</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>463-811</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dongguk University Ilsan Medical Center Obstetrics</name>
      <address>
        <city>Goyang-si</city>
        <state>Ilsandong-gu</state>
        <zip>10326</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Obstetrics / Grace Women's Hospital</name>
      <address>
        <city>Goyong-si</city>
        <state>Ilsandong-gu</state>
        <zip>10447</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital, Obstetrics</name>
      <address>
        <city>Daegu</city>
        <state>Jung-gu</state>
        <zip>41940</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pusan University Hospital Obstetrics</name>
      <address>
        <city>Pusan</city>
        <state>Seo-gu</state>
        <zip>602 739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Catholic Universith of Korea, Seoul ST. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Seocho-gu</state>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center, Sungkyunkwan Univ. School of Medicine</name>
      <address>
        <city>Kangnam-ku</city>
        <state>Seoul</state>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital / Department of Internal Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138 736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sanggye Paik Hospital-Inje University</name>
      <address>
        <city>Seoul</city>
        <zip>139-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Konkuk University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>143-729</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chungang University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>156-755</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>AJOU University Hospital</name>
      <address>
        <city>Suwon</city>
        <zip>443-380</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B2311067&amp;StudyName=Post%20Marketing%20Surveillance%20To%20Observe%20Safety%20And%20Efficacy%20Of%20Duavive</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B2311067&amp;StudyName=Post+Marketing+Surveillance+To+Observe+Safety+And+Efficacy+Of+Duavive</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B2311067&amp;StudyName=Post+Marketing+Surveillance+To+Observe+Safety+And+Efficacy+Of+Duavive+0.45mg%2F20mg</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B2311067&amp;StudyName=Post+Marketing+Surveillance+To+Observe+Safety+And+Efficacy+Of+Duavive+Tab+0.45mg%2F20mg</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2016</study_first_submitted>
  <study_first_submitted_qc>June 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2016</study_first_posted>
  <last_update_submitted>February 14, 2018</last_update_submitted>
  <last_update_submitted_qc>February 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

